Abstract 1600
Background
D2 gastrectomy followed by postoperative S-1 is the standard therapy for the patients (pts) with stage III gastric cancer (GC) in East Asia, but 40% of the pts develop a recurrence. We hypothesize that the perioperative capecitabine and oxaliplatin (CapeOx) might improve survival for clinical stage III GC.
Methods
In this phase II trial, the eligibility criteria included pathologically confirmed clinical SS/SE N1-3 M0 GC according to Japanese Classification of GC (JCGC) 3rd English Edition. Perioperative CapeOx consisted of three cycles of CapeOx (capecitabine; 2,000 mg/m2 for 14 days, oxaliplatin; 130 mg/m2 day 1) every 3 weeks as neoadjuvant chemotherapy (CT), followed by five cycles of adjuvant CapeOx after the D2 gastrectomy. The primary endpoint was the pathological response rate (pRR) according to JCGC (≥ Grade 1b). The planned sample size was 34 pts calculated on the hypothesis that the expected pRR was 65% and the threshold was 40%, with one-sided alpha of 0.05 and power of 90%.
Results
Thirty-seven pts were enrolled from Apr. 2016 to May. 2017, and fully evaluated for efficacy and toxicity. R0 and R1 resection were achieved in 29 and three pts, respectively. One pt underwent R2 resection, and four pts could not undergo surgical resection. Sixteen pts underwent total gastrectomy, and 17 pts underwent distal gastrectomy. The pRR was 54.1% (one-sided p = 0.058, 95% CI: 36.9-70.5). The relative dose intensity (RDI) of Capecitabine and Oxaliplatin were 90.7% and 92.0%, respectively. Twenty-seven pts received adjuvant therapy, and the RDI of capecitabine and Oxaliplatin were 80.9% and 63.4%, respectively. Grade 3/4 toxicities of neoadjuvant CT included neutropenia (8%), thrombocytopenia (8%), and anorexia (8%). Grade 3/4 toxicities of adjuvant CT included neutropenia (27%), diarrhea (8%), and anorexia (3%). Grade IIIa surgical complications included intraabdominal abscess (3%), bowel obstruction (3%), and anastomotic leakage (3%).
Conclusions
This phase II trial of perioperative CapeOx showed favorable antitumor activity with an acceptable safety profile for stage III GC, although pRR as primary endpoint did not meet the prespecified threshold.
Clinical trial identification
UMIN000021641.
Legal entity responsible for the study
Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG).
Funding
Yakult Honsha Co., Ltd.
Editorial Acknowledgement
Disclosure
D. Sakai: Belongs to a donated fund laboratory: Yakult Honsha Co., Ltd., Chugai Pharmaceutical Co., Ltd. T. Satoh: Honoraria, Consulting fee: Eli Lilly, Chugai, Merck Serono; Research funding (institution): Sanofi, Yakult Honsha, Chugai, Ono. All other authors have declared no conflicts of interest.
Resources from the same session
1159 - Molecular characterization and search for founding effects in Canarian families with Hereditary Breast and Ovarian Cancer Syndrome
Presenter: Elisenda Llabres Valenti
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3725 - Effect of the polymorphism rs2066844 of the NOD2 gene on colon cancer incidence in a high cardiovascular risk population. Modulation by gender
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3708 - Effect of the polymorphisms rs1476413, rs1801131, rs4846052 and rs6541003 of the MTHFR gene on prostate cancer in a high cardiovascular risk population
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5057 - Association of a genetic variant in cyclin-dependent kinase Inhibitor 2A gene with the increased risk of breast cancer
Presenter: Soodabeh Shahid Sales
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5970 - Investigating the role of HAT protein TIP60 in regulating functional dynamics of nuclear receptor PXR
Presenter: KARISHMA BAKSHI
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1360 - The role of downregulated SIRT3 expression in patients with hepatocellular carcinoma
Presenter: Hanhee Jo
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1634 - Prediction and Intervention of Colorectal Cancer Risk with Artificial Intelligent System
Presenter: Yang Ge
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4921 - Measuring the Efficiency of Cancer Care in Europe
Presenter: Rikard Althin
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1235 - Circulating cell-free DNA isolated from plasma of mesenteric veins predicts prognosis in stage II colorectal cancer patients
Presenter: Chih-Yung Yang
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5169 - _lonality of uterine carcinosarcoma as a factor of clinical prognosis.
Presenter: Natalia Levitskaya
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract